On Friday, Celldex Therapeutics, Inc. (NASDAQ:CLDX)’s shares inclined 0.37% to $13.53.
Celldex Therapeutics, Inc. (CLDX) stated business and financial highlights for the second quarter ended June 30, 2015.
Program Updates:
RINTEGA(R) (“rindopepimut”; “rindo”; CDX-110), an EGFRvIII(v3)-specific therapeutic vaccine for glioblastoma (GBM)
- In June, the independent Data Safety and Monitoring Board (DSMB) recommended continuation of the Phase 3 ACT IV study of RINTEGA(R) (rindopepimut) in patients with newly diagnosed glioblastoma as a result of a prespecified interim analysis assessing safety, futility and efficacy at 50% of events (deaths). The ACT IV study is a randomized, double-blind, placebo controlled study of RINTEGA plus GM-CSF added to standard of care temozolomide in patients with newly diagnosed, surgically resected, EGFRvIII-positive glioblastoma. 745 patients were enrolled into ACT IV to reach the required 374 patients with minimal residual disease (assessed by central review) needed for analysis of the primary overall survival endpoint. All patients, counting those with disease that exceed this threshold, will be comprised of in a secondary analysis of overall survival in addition to analyses of progression-free survival, safety and tolerability, and quality of life. The second interim analysis is predictable to occur in late 2015/early 2016.
Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The companys lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, in addition to in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, in addition to in Phase II study for the treatment of metastatic melanoma. It also has various earlier stage drug candidates in clinical development, counting varlilumab (CDX-1127), a fully human therapeutic monoclonal antibody for cancer indications; CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells for cancer indications; and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor.
Western Digital Corp(NASDAQ:WDC)’s shares dropped -0.44% to $79.44.
WD®, a Western Digital® (WDC) company, and world leader in storage solutions, recently declared the expansion of its award-winning WD Red Pro hard drive line with the release of 5 TB and 6 TB capacities. The WD Red Pro family is ideal for NAS (network attached storage) systems having up to 16 drive bays and serving businesses with more expansive storage needs than the standard WD Red drives.
Shipping now, WD Red Pro 5 and 6 TB drives leverage an improved design and 128 MB cache to deliver data transfer rates of 214 megabytes per second (MB/s). WD’s NASware™ 3.0 features technology promoting data protection, high NAS performance and reliable integration.
WD Red Pro 6 TB hard drives feature the following:
Up to 16 Bay Shock Protection – Equipped with a multi- axis shock sensor, the drive automatically detects subtle shock events and, together with dynamic fly height technology, adjusts each read-write function to compensate and protect the data, further protecting the drive in large 1- to 16-bay NAS environments.
NASware 3.0 – Exclusive advanced firmware enables seamless integration, robust data protection and optimal performance for systems operating in the demanding NAS environment.
Vibration Protection – Hardware vibration compensation technology monitors the drive to correct both linear and rotational vibration in real time, further increasing drive reliability and enabling high performance in higher vibration systems caused from drive to drive vibration in addition to from the high speed fans used to cool the larger systems.
Western Digital Corporation, together with its auxiliaries, engages in the development, manufacture, sale, and provision of data storage solutions that enable consumers, businesses, governments, and other organizations to create, manage, experience, and preserve digital content worldwide. The company’s product portfolio comprises hard disk drives (HDDs), solid-state drives (SSDs), direct attached storage solutions, personal cloud network attached storage solutions, and public and private cloud data center storage solutions.
At the end of Friday’s trade, Ascent Solar Technologies, Inc. (NASDAQ:ASTI)‘s shares surged 16.09% to $0.128.
Ascent Solar Technologies, Inc. ( ASTI), a developer of state-of-the-art, flexible thin-film photovoltaic modules, integrated into the Company’s EnerPlex™ series of consumer products, stated results for the second quarter ending June 30, 2015.
Q2 & H1-2015 Financial Results
Total revenue for the second quarter of 2015 was $2.2M, up about 105% from the same period last year. Loss from Operations in the quarter was ($6.9M), an improvement of about $1M or 12.6% from ($7.9M) in the same period last year.
For the six months ended June 30, 2015, total revenue was $2.9M, up from $1.8M in H1-2014 or about 57% growth. Loss from Operations improved by about 11% or $1.7M from ($15.5M) in H1-2014 to ($13.8M) in H1-2015, due to a combination of increasing sales and improved operational efficiencies while keeping operating expenses marginally down. These expenses are predictable to remain relatively flat while we continue to ramp up on revenue growth.
Ascent Solar Technologies, Inc., a development stage company, designs and manufactures photovoltaic integrated consumer electronics; and portable power applications for commercial and military users. The company offers Surfr, a battery and a solar case for the Apple iPhone 4/4S smart phone, in addition to for the Samsung Galaxy S III smart phone; EnerPlex Kickr, a portable solar charging device; and EnerPlex Jumpr, a portable power bank.
Hudson City Bancorp, Inc. (NASDAQ:HCBK), ended its Friday’s trading session with -2.64% loss, and closed at $9.58.
Hudson City Bancorp, Inc. (HCBK), the holding company for Hudson City Savings Bank (the “Bank”), has declared that it will engage in a month long campaign during August 2015 to address seasonal shortages at local area food pantries. Summer months tend to impact food distribution and resources as children are not receiving meals in school and donation levels decrease. Working with the Center for Food Action (CFA), a 501(c)3 organization, Hudson City Savings Bank will collect food and monetary donations from our employees and the public in our Bergen and Passaic County branches and Administrative offices. Additionally, Hudson City Savings Bank will provide a can for can match of all food items collected during the campaign, and a dollar for dollar match of all monetary donations made by Hudson City employees.
Hudson City Bancorp, Inc. maintains its corporate offices in Paramus, New Jersey. Hudson City Savings Bank, a well-established community financial institution serving its customers since 1868, is the largest thrift institution headquartered in New Jersey. Hudson City Savings Bank presently operates a total of 135 banking offices in the New York metropolitan and surrounding areas.
Hudson City Bancorp, Inc. operates as the holding company of Hudson City Savings Bank that provides various banking products and services in the United States. Its deposit products comprise passbook and statement savings accounts, interest-bearing transaction accounts, checking accounts, money market accounts, and time deposits, in addition to IRA accounts and qualified retirement plans.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
